SAB Biotherapeutics, Inc. SABS
3.10 USD +0.07 (+2.31%)
At closeNov 9, 2026, 4:36 PM EST
3.09 -0.01 -0.33%
After hours · Nov 9, 4:36 PM ET
3.05 Day range 3.18
2.44 52-week range 5.15
- YTD
- -17.11%
- 1 year
- -3.13%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
benzinga.com SAB Biotherapeutics Q3 2026 Earnings Call Transcript SAB Biotherapeutics (NASDAQ:SABS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026
benzinga.com FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…
benzinga.com SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 Diabetes Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a…
benzinga.com Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13 Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Overweight rating and announces Price Target of $13.
benzinga.com Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16 Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $14 to $16.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst ratings page. Barclays, Wells Fargo, Piper Sandler, Leerink Partners, Truist Securities, and…
benzinga.com Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12 Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperform and raises the price target from $7 to $12.- benzinga.com HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $10 price target.
benzinga.com Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11 Citigroup analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.
benzinga.com This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Wall Street analysts changed outlook on top names. See full ratings page for upgrades, downgrades, and initiations. Analysts view QUIK stock positively.- benzinga.com Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11 Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.
benzinga.com HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10 HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $7 to $10.- benzinga.com Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
benzinga.com SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate. SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. This is a 37.5 percent increase over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price Target Rodman & Renshaw analyst Seema Sheoran reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $13 price target.
- benzinga.com Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes The executed agreement is valued at approximately $50 million, of which $36 million is contingent on future regulatory approval and downstream milestones.Under the terms of the agreement, Emergent…
- benzinga.com SAB Biotherapeutics To Present Oral Presentation, Multiple Poster Presentations At 21st Immunology of Diabetes Society Congress On Its SAB-142 Program SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…
- benzinga.com SAB Biotherapeutics Launches Public Stock Offering To Fund Development Of Type 1 Diabetes Therapy; No Terms Disclosed SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…
- benzinga.com HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $7 HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $9 to $7.
benzinga.com SAB Biotherapeutics Announces Additional Data From Phase 1 HUman Anti-Thymocyte Biologic In First-In-MAN Clinical Trial Of SAB-142; Results Demonstrated Early Signals Of C-peptide Preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 dataMIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a…- benzinga.com UBS Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $7 UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $7.
- benzinga.com Guggenheim Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $15 Guggenheim analyst Yatin Suneja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $15.
- benzinga.com Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
- benzinga.com SAB Biotherapeutics Announces Confirmatory Data From Phase 1 Trial Of SAB-142 In Single- And Multiple-Ascending Dose Among Healthy Volunteers, Including Re-Dosed Cohort, And T1D Patients Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases,…
- benzinga.com Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
- benzinga.com SAB Biotherapeutics To Present Phase 1 Data Demonstrating SAB-142's Multi-Specific Mechanism Of Action, Sustained Immunomodulation, Favorable Safety Profile Without Serum Sickness Or Anti-Drug Antibodies, And A Novel Pharmacokinetic Assay For Measuring The Drug SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases,…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
- benzinga.com Leerink Partners Initiates Coverage On SAB Biotherapeutics with Outperform Rating, Announces Price Target of $7 Leerink Partners initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Outperform rating and announces Price Target of $7.
- benzinga.com SAB Biotherapeutics To Present At The 61st Annual Meeting Of The European Association For The Study Of Diabetes (Easd) Being Held September 15 – 19, 2025 At The Viecon - Vienna Congress & Convention Center In Vienna, Austria MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $12 Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $20 to $12.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $9 HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $10 to $9.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com SAB BIO Raises $175M In Oversubscribed Private Placement To Fully Fund Phase 2b SAFEGUARD Trial For Autoimmune Type 1 Diabetes Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $20 Price Target Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $20 price target.
- benzinga.com HC Wainwright & Co. Assumes SAB Biotherapeutics at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $10.